Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The Food and Drug Administration (FDA) has granted accelerated approval to Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of individuals 6 years of age and older with unresectable or metastatic solid tumors with BRAF…